Mentions:
1: Will Quince (Con - Colchester) that we are getting it right as we develop the strategy.I would also like to touch on gene and cell therapies - Speech Link
Asked by: Sammy Wilson (Democratic Unionist Party - East Antrim)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the availability of non-invasive cancer treatment technologies in the NHS.
Answered by Will Quince
The adoption of new treatments, including increasing the number of minimally invasive cancer treatments, into the National Health Service in England is generally the result of National Institute for Health and Care Excellence (NICE) guidance and commissioner decisions. Both NHS England and integrated care boards (ICBs) are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by NICE.
Where treatments are approved by NICE through the Technology Appraisals programme, the NHS is required to make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.
The NHS continues to increase investment in minimally invasive cancer therapies and radiotherapy and chemotherapy services. Since April 2022, the responsibility for investing in new radiotherapy machines has sat with local systems. This is supported by the 2021 Spending Review, which set aside £12 billion in operational capital for the NHS from 2022 to 2025.
Asked by: Stephanie Peacock (Labour - Barnsley East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support his Department has provided to NHS trusts to help ensure that non-invasive cancer treatments take place before patients’ conditions worsen.
Answered by Will Quince
The National Health Service continues to increase investment in minimally invasive cancer therapies and radiotherapy and chemotherapy services. Since April 2022, the responsibility for investing in new radiotherapy machines has sat with local systems. This is supported by the 2021 Spending Review, which set aside £12 billion in operational capital for the NHS from 2022 to 2025.
In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years to support delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity for cancer.
Jul. 20 2023
Source Page: Non-technical summaries granted in 2023Found: Most of the imaging methods used are either non-invasive or minimally invasive.
Jul. 20 2023
Source Page: Non-technical summaries granted in 2023Found: The project is about optimising animal experience and the sampling techniques used are minimally invasive
Oral Evidence Jul. 19 2023
Inquiry: Future cancerFound: cancer is likely to be located.
Jul. 05 2023
Source Page: I. Letter dated 30/06/2023 from Steve Barclay MP to all MP The NHS Long Term Plan. 2p. II. NHS Long Term Workforce Plan. 151p.Found: moving planned care from overnight stays to day -case settings, with surgical techniques becoming less invasive
Jun. 30 2023
Source Page: What the NHS Long Term Workforce Plan means for youFound: moving planned care from overnight stays to day -case settings, with surgical techniques becoming less invasive
Written Evidence Jun. 28 2023
Inquiry: Future cancerFound: FCR0065 - Future cancer The British Liver Trust Written Evidence
Written Evidence Jun. 28 2023
Inquiry: Future cancerFound: FCR0072 - Future cancer All-Party Parliamentary Group on Minimally Invasive Cancer Therapies Written